IP Library Granted Patent US 12,396,999
Granted Patent B2
US 12,396,999 · App. 17/874,838 · Granted Aug 26, 2025

Composition of ferric maltol for oral administration

Inventors: Ravishanker Kovi (North Brunswick, NJ); Prasad Vure (Vadodara, IN); Raghu Rami Reddy Kasu (Pearl River, NY); Thupalli Ajey Kumar Reddy (Bangalore, IN); Yekkanti Vamshi (Bangalore, IN); Jayraman Kannappan (Vadodara, IN); Hardik Vyas (Vadodara, IN)
Assignee: RK PHARMA INC.
A61K31/555A61K9/485A61K9/4858A61K9/4866
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,396,999
App. No.
17/874,838
Granted
Aug 26, 2025
Kind
B2
Abstract

The invention relates to an improved composition of ferric maltol or ferric trimaltol for the treatment of iron deficiency, wherein the composition comprises the active ferric maltol or ferric trimaltol lower than 60% of the total composition weight. The compositions further can be a capsule or tablet or any other pharmaceutical solid dosage form, preferably a capsule in a hard gelatin in a size of 0 or 1, for oral administration.

Claims (2)

1. A capsule dosage form consisting of: ferric maltol or ferric trimaltol as active ingredient and pharmaceutically acceptable excipients, wherein ferric maltol or ferric trimaltol is acetic acid solvate form in a formulation consisting of lower than 55% of ferric maltol or ferric trimaltol of the combined weight with excipients and with a total impurity lower than 1%, and with a 1-(2-furyl) ethanol lower than 0.5% at 40° C./75% RH.

2. The formulation of claim 1 , wherein the ferric maltol or ferric trimaltol formulation has a concentration equivalent to 25 to 35 mg of elemental iron.

Assignments (1)
SECURITY INTEREST Recorded May 8, 2024
From: RK PHARMA INC.
To: CITIBANK, N.A.
Reel/Frame 067343/0089 →
Continuity (2)
Provisional Application 63230109 · Aug 6, 2021
Related Publication 20230054302A1 · Feb 23, 2023
References Cited (3)
US 20170304314A1 · Mallard · 2017 [cited by examiner]
European Medicines Agency, titled “Committee for Medicinal Products for Human Use. Assessment Report on Feraccru.” ( Dec. 17, 2015) (Year: 2015). [cited by examiner]
Federal Drug Administration-Center for Drug Evaluation and Research, titled “Accrufer (ferric maltol) Capsules-Product Quality Reviews.” (Sep. 27, 2018) (Year: 2018). [cited by examiner]